Categories  |  Inventors

Technology Overview

OHSU # 2779 — Novel agents for the detection and treatment of bladder cancer


Given the prevalence of bladder cancer in the United States, it is surprising that a limited number of treatments exist for this disease.  To address this unmet need, researchers at Oregon Health & Science University have developed novel agents for use in both detecting and treating early stage, non-invasive bladder cancer. 

Technology Overview

About half of all bladder cancers are identified early, when they are in the non-invasive stage and are limited to the innermost layer of the bladder wall.  Despite current treatment options, non-invasive bladder cancers are likely to recur.  This results in high lifetime healthcare costs for repeated surveillance and treatment of these patients, and makes these cancers the most expensive of all cancers to treat per capita.  The difficulty in treating early stage bladder cancer and the high cost associated with it underscore the need to find an effective and easy method of bladder cancer diagnosis and treatment when the cancer is still in the non-invasive stage.

OHSU’s novel agents can be used to specifically target early stage tumor cells in the bladder by taking advantage of the altered architecture of the tumor cell, compared to that of the surrounding normal cells.  The agents can be conjugated to either i) a detectable marker for visible detection of early stage cancer or ii) an anti-tumor agent for tumor cell killing, and thus have potential for use in screening and therapeutic applications.  Moreover, the agents can be administered directly into the bladder, avoiding systemic exposure.  This technology can be applied to other disorders where the normal architecture of an epithelial cell is lost.

Licensing Opportunity

This technology is available for exclusive licensing and/or collaborative co-development.



Published United States WO 2021/202592
Published United States US 2023/0140976 A1